On June 25th, join OBIO for a unique opportunity to hear from experienced investors and analysts about how VCs think about valuation and how valuation is translated into deal structure.
Find out more about:
- ROI needed for investors
- Valuation methods commonly used
- Criteria for selecting comparable companies
- Characteristics of equity and debenture instruments
- Consequences of dilution and follow-on investment
- Calculating exit payouts
- Red flags and how to prepare to discuss valuation with investors
Richard Meadows is an OBIO Director. He was selected by FORBES as one of the top ten Life Science Investors in North America in 2013. He was a Managing Partner, and co-founder of CTI Capital, Fund I, a $100M Life Sciences Fund in Canada that co-lead financings in ENOBIA (exit for $1.081B) and TARGEGEN (exit for $565M). He joined the Fund from his previous position as a Venture Partner with Vantage Point Venture Partners (VPVP), a US$2.8 billion private Equity fund based in San Bruno, California. Prior to VPVP, Richard was also a Partner in the Biotechnology Group of CDP Capital Technology Ventures ($1.2 billion). Richard is currently raising a BioInnovation Capital Fund and in parallel has been raising money for start-ups in the med device space; and an early stage speciality pharma company in Europe ($64M USD closed May 2018).
Andy Haigh is the Chief Operating Officer of Adapsyn Bioscience and has been working with the company since its inception. Prior to Adapsyn, he was the second employee at Formation Biologics, an antibody-drug conjugates company that has raised over $20 million to date to fuel clinical development. He also spent five years at Lumira Capital, a leading Canadian venture capital firm, where he executed both equity and debt transactions. Andy holds a PhD in Biology from Dalhousie University and an MBA from the Ivey Business School, which he attended on full scholarship from the Canadian Institutes of Health Research.